Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2026)
Treace Medical Concepts (TMCI) reported Cash from Financing Activities of -$588000.0 for Q1 2026, down 108.51% on a YoY basis from $6.9 million in Q1 2025, and down 142.55% quarter-over-quarter from $1.4 million in Q4 2025.
Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Treace Medical Concepts has reported Cash from Financing Activities for 7 years, with the latest figure at -$588000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 108.51% year-over-year to -$588000.0; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (up 2711.11% YoY), and the FY2025 full-year result was $2.1 million, up 1198.12% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$588000.0, down from $1.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $107.9 million in Q1 2023, with the low at -$588000.0 in Q1 2026.
- Historically, Cash from Financing Activities has averaged $7.8 million across 5 years, with a median of $297000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 7762.9% — and 2025, when it plunged 225.0%.
- Treace Medical Concepts' Cash from Financing Activities stood at $297000.0 in 2022, then sank by 44.44% to $165000.0 in 2023, then plunged by 84.24% to $26000.0 in 2024, then surged by 5215.38% to $1.4 million in 2025, then slumped by 142.55% to -$588000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$588000.0 (Q1 2026), $1.4 million (Q4 2025), and -$10000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Treace Medical Concepts | 274.20 Mn | 222.34 Mn | 37.41 Mn | -588,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -588,000.00 |
| Mar 31, 2026 | -588,000.00 |
| Dec 31, 2025 | 1.38 Mn |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | -10,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | 987,000.00 |
| Jun 30, 2025 | 987,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Mar 31, 2024 | -185,000.00 |
| Mar 31, 2024 | -185,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Dec 31, 2023 | 165,000.00 |